Related Experiment Video
Updated: Jun 17, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin
Ei Tae Kim1, Lee Hoo Kim1, Jung Il Lee2
1Department of Ophthalmology, Inha University School of Medicine, Incheon, Korea.
Background:
To assess the nature, incidence, and risk factors of retinopathy associated with pegylated interferon and ribavirin combination therapy in chronic hepatitis C patients.
Methods:
Thirty-two patients with chronic hepatitis C were examined prospectively for changes in fundus findings while they were being treated with pegylated interferon and ribavirin. Patients were followed with sequential ocular examinations for a maximum of 36 weeks.
Results:
Eleven of the 32 patients (34.4%) developed retinopathy. Cotton-wool spots were found in six patients, retinal hemorrhages in four, and branch retinal vein occlusion in one (one eye). Hypertension was found to be the most significant risk factor for developing retinopathy.
Conclusion:
Significant ocular complications such as an irreversible decrease of visual acuity may develop in patients treated with pegylated interferon. The valid risk factor for developing retinopathy is hypertension. The high rate of retinopathy in patients with hypertension suggests that patients should be carefully monitored.
Related Concept Videos
Hepatitis
Diabetic Retinopathy
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test